{
    "clinical_study": {
        "@rank": "132620", 
        "acronym": "Anti-PD-1 HCC", 
        "arm_group": [
            {
                "arm_group_label": "Non-infected: Nivolumab", 
                "arm_group_type": "Experimental", 
                "description": "Nivolumab 0.3 g/kg or 1 mg/kg or 3 mg/kg or 10 mg/kg intravenous solution, Every 14 days, 3 doses per each cycle of 42 days, 16 cycles /48 doses depending on response"
            }, 
            {
                "arm_group_label": "HCV-infected: Nivolumab", 
                "arm_group_type": "Experimental", 
                "description": "Nivolumab 0.3 g/kg or 1 mg/kg or 3 mg/kg or 10 mg/kg intravenous solution, Every 14 days, 3 doses per each cycle of 42 days, 16 cycles /48 doses depending on response"
            }, 
            {
                "arm_group_label": "HBV-infected: Nivolumab", 
                "arm_group_type": "Experimental", 
                "description": "Nivolumab 0.1 mg/kg or 0.3 g/kg or 1 mg/kg or 3 mg/kg or 10 mg/kg intravenous solution, Every 14 days, 3 doses per each cycle of 42 days, 16 cycles /48 doses depending on response"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety, pharmacokinetics, immunoregulatory\n      activity, pharmacodynamics and preliminary anti-tumor activity of BMS-936558 in subjects\n      with advanced hepatocellular carcinoma (HCC)"
        }, 
        "brief_title": "Dose Escalation Study of Nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in Patients (Pts) With Advanced Hepatocellular Carcinoma (HCC) With or Without Chronic Viral Hepatitis", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatocellular Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Hepatitis", 
                "Hepatitis A", 
                "Carcinoma, Hepatocellular"
            ]
        }, 
        "detailed_description": {
            "textblock": "Study Classification: Pharmacokinetics/Pharmacodynamics"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "For more information regarding BMS clinical trial participation, please visit\n        www.BMSStudyConnect.com\n\n        Inclusion Criteria:\n\n          -  Subjects with histological confirmation of advanced hepatocellular carcinoma;\n             subjects must have progressive disease following or be intolerant of at least one\n             line of therapy or refuse sorafenib treatment; subjects must be off sorafenib\n             treatment for at least 28 days prior to first dose\n\n          -  Child-Pugh score of B7\n\n          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1\n\n        Exclusion Criteria:\n\n          -  Subjects with brain metastasis\n\n          -  Encephalopathy\n\n          -  Any prior or current clinically significant ascites as measured by physical\n             examination and that requires active paracentesis for control; any history of\n             clinically meaningful variceal bleeding within the last three months\n\n          -  Active coinfection with both hepatitis B and C\n\n          -  Hepatitis D infection in subjects with hepatitis B"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 3, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01658878", 
            "org_study_id": "CA209-040", 
            "secondary_id": "2012-001514-42"
        }, 
        "intervention": {
            "arm_group_label": [
                "Non-infected: Nivolumab", 
                "HCV-infected: Nivolumab", 
                "HBV-infected: Nivolumab"
            ], 
            "intervention_name": "Nivolumab", 
            "intervention_type": "Biological", 
            "other_name": "BMS-936558"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 7, 2014", 
        "link": [
            {
                "description": "BMS Clinical Trial Information", 
                "url": "http://ctr.bms.com/ctd/start.do"
            }, 
            {
                "description": "BMS clinical trial educational resource", 
                "url": "http://www.bms.com/studyconnect/Pages/home.aspx"
            }, 
            {
                "description": "Investigator Inquiry form", 
                "url": "http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"
            }, 
            {
                "description": "FDA Safety Alerts and Recalls", 
                "url": "http://www.fda.gov/MEDWATCH/safety.htm"
            }
        ], 
        "location": [
            {
                "contact": {
                    "last_name": "Anthony El-Khoueiry, Site 0008"
                }, 
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90033"
                    }, 
                    "name": "Usc Norris Comprehensive Cancer Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Theodore Welling, Site 0002"
                }, 
                "facility": {
                    "address": {
                        "city": "Ann Arbor", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48109"
                    }, 
                    "name": "Univ Of Michigan"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Todd Crocenzi, Site 0001"
                }, 
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97213"
                    }, 
                    "name": "Providence Portland Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0005"
                }, 
                "facility": {
                    "address": {
                        "city": "Hong Kong", 
                        "country": "Hong Kong", 
                        "zip": "8525"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0006"
                }, 
                "facility": {
                    "address": {
                        "city": "Hong Kong", 
                        "country": "Hong Kong"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0007"
                }, 
                "facility": {
                    "address": {
                        "city": "Singapore", 
                        "country": "Singapore", 
                        "zip": "308433"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pamplona", 
                        "country": "Spain", 
                        "zip": "31192"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Active, not recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Hong Kong", 
                "Singapore", 
                "Spain"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase I Dose Escalation Study to Investigate the Safety, Immunoregulatory Activity, Pharmacokinetics, and Preliminary Antitumor Activity of Anti-Programmed-Death-1 (PD-1) Antibody (BMS-936558) in Advanced Hepatocellular Carcinoma in Subjects With or Without Chronic Viral Hepatitis", 
        "overall_contact": {
            "email": "Clinical.Trials@bms.com", 
            "last_name": "Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:"
        }, 
        "overall_contact_backup": {
            "last_name": "First line of the email MUST contain NCT# and Site #."
        }, 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol-Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
                "Singapore: Health Sciences Authority", 
                "Hong Kong: Department of Health"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "All non-serious adverse events will be collected from Day 1 until 100 days after the subject's last dose of BMS-936558", 
                "measure": "Incidence of worst adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 100 days after the last dose of BMS-936558"
            }, 
            {
                "measure": "Incidence of clinical laboratory test abnormalities including hematology and serum chemistry abnormalities", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 214"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01658878"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Objective response rate and disease control rate", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 214"
            }, 
            {
                "measure": "Frequency of subjects with increase in anti-drug antibodies (ADA) levels", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 214"
            }, 
            {
                "measure": "Geometric means and coefficients of variation for the pharmacokinetic parameter of serum concentration achieved at the end of the dosing interval (trough concentration, Cmin)", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 214"
            }, 
            {
                "measure": "Geometric means and coefficients of variation for the pharmacokinetic parameter of maximum observed serum concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 214"
            }, 
            {
                "measure": "Geometric means and coefficients of variation for the pharmacokinetic parameter of serum concentration achieved at the end of the infusion (Ceoinf)", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 214"
            }, 
            {
                "measure": "Geometric means and coefficients of variation for the pharmacokinetic parameter of area under the concentration-time curve from time zero to the time of the last quantifiable concentration [AUC(0-T)]", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 214"
            }, 
            {
                "measure": "Geometric means and coefficients of variation for the pharmacokinetic parameter of area under the concentration-time curve in one dosing interval [AUC(TAU)]", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 214"
            }, 
            {
                "measure": "Medians, minimum, and maximum for the pharmacokinetic parameter of time to maximum observed concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 214"
            }
        ], 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}